Related Experiment Video
Updated: Jul 15, 2026
Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens
Published on: July 29, 2011
Radioresistant glioma stem cells--therapeutic obstacle or promising target?
1Brighton and Sussex Medical School, Genome Damage and Stability Centre, University of Sussex, Falmer, Brighton BN1 9RQ, UK. a.j.chalmbers@sussex.ac.uk
Abstract:
Attempts to improve outcomes for patients with glioblastoma multiforme have focused largely on dose intensification and multimodal therapy and have been met with limited success. An alternative approach involves identifying and targeting the mechanisms responsible for tumour resistance. Recent data suggests that these high grade malignancies harbour a population of glioma stem cells that are both radioresistant and capable of initiating tumour regrowth. Furthermore, the radioresistant phenotype may be the consequence of constitutively upregulated and hyper-responsive cell cycle checkpoint pathways. This article considers whether these findings herald the dawn of a new era of effective, targeted therapy for this refractory tumour.
Insights
Glioblastoma multiforme treatment has seen limited success. Targeting radioresistant glioma stem cells, potentially due to cell cycle checkpoints, offers a new therapeutic approach for this difficult cancer.
Area of Science:
- Neuro-oncology
- Cancer biology
- Radiation oncology
Background:
- Glioblastoma multiforme (GBM) treatment outcomes remain poor despite dose intensification and multimodal therapy.
- Tumor resistance is a major challenge in treating high-grade gliomas.
- Glioma stem cells (GSCs) are implicated in GBM radioresistance and tumor recurrence.
Purpose of the Study:
- To explore the role of glioma stem cells in glioblastoma multiforme radioresistance.
- To investigate the potential of targeting GSCs and their associated pathways for effective GBM therapy.
Main Methods:
- Review of recent scientific literature on glioblastoma stem cells.
- Analysis of data linking GSC radioresistance to cell cycle checkpoint pathways.
- Discussion of potential targeted therapeutic strategies.
Main Results:
- Glioma stem cells are radioresistant and drive tumor regrowth in glioblastoma.
- The radioresistant phenotype of GSCs may stem from upregulated cell cycle checkpoint pathways.
- Targeting these specific pathways could overcome treatment resistance.
Conclusions:
- Targeting glioma stem cells represents a promising new strategy for glioblastoma treatment.
- Understanding GSC biology and resistance mechanisms is crucial for developing effective therapies.
- This approach may usher in a new era of targeted treatments for refractory glioblastoma.
